Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on May 19, 2020. The filing discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors appointed Dr. Jack Reich as a Class III member, effective immediately, increasing the Board size to seven members.
- Committee Assignments: Dr. Reich will serve on the Audit Committee and the Nominations and Corporate Governance Committee.
- Compensation Arrangement: Dr. Reich was awarded an option to purchase 90,000 shares of common stock at an exercise price of $1.47 per share. The options vest pro rata monthly over 36 months and are exercisable for 10 years. He will also receive a cash retainer for Board and committee service.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that there are no family relationships between Dr. Reich and existing directors or officers, and no undisclosed material interests in transactions.
Investor Verification Checklist
- Verify the total number of outstanding options granted to Dr. Reich (90,000 shares) and the vesting schedule.
- Confirm the current total size of the Board of Directors (now seven members).
- Review the Company's most recent 10-Q or 10-K for financial metrics not included in this 8-K.
- Check the exercise price of $1.47 against the current market price of ADIL common stock.